Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema

Table 3

Best-corrected visual acuity (BCVA) over time.

	Measured BCVA
Visit	Baseline	30 days	60 days	90 days
Mean (logMAR ± SD)	20/105 (0.72 ± 0.34)	20/60 (0.48 ± 0.28)	20/53 (0.42 ± 0.30)	20/57 (0.46 ± 0.39)
Median, logMAR (min, max)	0.55 (0.4, 1.39)	0.50 (0.00, 1)	0.45 (0.00, 1)	0.40 (0.00, 1.39)
	Change from Baseline in BCVA
Visit	Baseline	30 days	60 days	90 days
Mean, logMAR ± SD	not applicable	−0.24 ± 0.30	−0.30 ± 0.28	−0.26 ± 0.30
Median, logMAR (min, max)		0.15 (−0.20, 0.99)	0.30 (−0.10, 0.99)	0.25 (−0.30, 0.99)
value		0.007	0.0008	0.004

^∗Weighted t-test for change versus baseline.